New CAR T-cell Therapy Seen to Induce Lasting Remission in Advanced Multiple Myeloma PatientsMyeloma Research NewsAn ongoing Phase 1 trial testing a novel CAR T-cell therapy has shown promising results in relapsed or treatment-resistant (refractory) mu… Continue reading
HealioOutcomes of Primary Total Knee Arthroplasty in Patients With Hematopoietic Stem Cell TransplantationHealioPatients who have undergone hematopoietic stem cell transplantation to treat underlying bone marrow pathology represent a unique and potenti… Continue reading
News-Medical.net |
Researchers find long-lasting benefits of gene therapy in dog model of myotubular myopathy
News-Medical.net Researchers who previously showed that a gene therapy treatment could save the lives of dogs with a deadly disease called myotubular myopathy—a type of muscular dystrophy that affects the skeletal muscles—have found that the therapy is long-lasting. |
FierceBiotech |
As Novartis preps for first CAR–T FDA AdComm, Juliet data revealed
FierceBiotech The FDA ‘breakthrough’ tagged Juliet data, which many have been waiting for to see how well it could stack up against rival Kite Pharma, was assessing CTL019 (a.k.a tisagenlecleucel) in 51 relapsing/remitting diffuse large B-cell lymphoma (r/r DLBCL) … Novartis touts new T–cell therapy data in race for FDA approvalReuters Novartis’ CAR–T stacks up to Kite in lymphomaBioPharma Dive Novartis’ posts landmark CAR–T data as head-to-head rivalry with Kite Pharma loomsEndpoints News GlobeNewswire (press release) all 8 news articles » |
FierceBiotech |
As Novartis preps for first CAR–T FDA AdComm, Juliet data revealed
FierceBiotech It’s been a big week for CAR–T: Novartis, Juno, Kite, Bluebird Bio and Nanjing Legend Biotech all posted positive data for the cutting-edge experimental cancer class at ASCO, and now Novartis has revealed the long-awaited interim Juliet data for its … Novartis touts new T–cell therapy data in race for FDA approvalReuters Novartis’ CAR–T stacks up to Kite in lymphomaBioPharma Dive Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCLGlobeNewswire (press release) |
Reuters |
Novartis touts new T–cell therapy data in race for FDA approval
Reuters Globally, there are some 183 CAR–T trials underway. In March, Novartis filed CTL019 with the U.S. Food and Drug Administration for fast-track approval in B-cell acute lymphoblastic leukemia (ALL) in young patients. The FDA has scheduled a July 12 … As Novartis preps for first CAR–T FDA AdComm, Juliet data revealedFierceBiotech Novartis posts landmark CAR–T data as head-to-head rivalry with Kite Pharma loomsEndpoints News Novartis’ CAR–T stacks up to Kite in lymphomaBioPharma Dive GlobeNewswire (press release) all 9 news articles » |